key: cord-0931474-ul602otg authors: Liu, Hejun; Wu, Nicholas C.; Yuan, Meng; Bangaru, Sandhya; Torres, Jonathan L.; Caniels, Tom G.; Schooten, Jelle van; Zhu, Xueyong; Lee, Chang-Chun D.; Brouwer, Philip J.M.; Gils, Marit J. van; Sanders, Rogier W.; Ward, Andrew B.; Wilson, Ian A. title: Cross-neutralization of a SARS-CoV-2 antibody to a functionally conserved site is mediated by avidity date: 2020-08-03 journal: bioRxiv DOI: 10.1101/2020.08.02.233536 sha: a8e6fde6d29bd2bbced2571a40c67e22805a593b doc_id: 931474 cord_uid: ul602otg Most antibodies isolated from COVID-19 patients are specific to SARS-CoV-2. COVA1-16 is a relatively rare antibody that also cross-neutralizes SARS-CoV. Here we determined a crystal structure of COVA1-16 Fab with the SARS-CoV-2 RBD, and a negative-stain EM reconstruction with the spike glycoprotein trimer, to elucidate the structural basis of its cross-reactivity. COVA1-16 binds a highly conserved epitope on the SARS-CoV-2 RBD, mainly through a long CDR H3, and competes with ACE2 binding due to steric hindrance rather than epitope overlap. COVA1-16 binds to a flexible up conformation of the RBD on the spike and relies on antibody avidity for neutralization. These findings, along with structural and functional rationale for the epitope conservation, provide a blueprint for development of more universal SARS-like coronavirus vaccines and therapies. 6 neutralize SARS-CoV-2 pseudovirus even up to 13 μg/mL. A similar effect is also 116 observed for SARS-CoV pseudovirus, which is neutralized by COVA1-16 IgG at an IC50 117 of 29 μg/mL, but not by COVA1-16 Fab even up to 67 μg/mL ( Figure 2E ). Of note, COVA1-118 16 is less potent against authentic SARS-CoV-2 (IC50 = 0.75 μg/mL) [6] . Whether such a 119 difference is due to variation in S protein density on the viral surface versus pseudovirus 120 or to other factors deserves future investigation. It will also be informative to compare the Next we examined the molecular details of the interactions between COVA1-16 and 133 SARS-CoV-2. COVA1-16 binding to the RBD is dominated by the heavy chain, which 134 accounts for 82% of its total buried surface area (BSA, 694 Å 2 out of a total of 844 Å 2 ). Most of the interactions are mediated by CDR H3 (Figure 3A ), which contributes 70% (594 136 Å 2 ) of the total BSA. CDR H3 forms a beta-hairpin with a type I beta-turn at its tip and is 137 largely encoded by IGHD3-22 (from VH N98 to VH Y100f, Figure S1C and Figure 3B ). The (Table S2 ). The positively charged guanidinium of VH R100b also 143 interacts with the negative dipole at the C-terminus of a short α-helix in the RBD (residues 144 Y365 to Y369). Interestingly, VH R100b is a somatically mutated residue (codon = AGG in 145 the IGHD3-22-encoded region, where the germline residue is a Ser (codon = AGT, Figure 146 S1C). The short Ser side chain would likely not contact the RBD nor provide electrostatic 147 complementarity. Interestingly, a somatic revertant VH R100bS actually improved binding 148 affinity of COVA1-16 to the RBD, mostly due to an increased on-rate ( Figure S5 ). Nevertheless, COVA1-16 has a much slower off-rate than its VH R100bS mutant, which 150 may have led to its selection. The CDR H3 tip also interacts with the RBD through 151 hydrophobic interactions between VH Y99 and the aliphatic portion of RBD K378, as well 152 as a π−π interaction between VH Y100 and the RBD V382-S383 peptide backbone ( Figure 153 3B). CDR H3 forms an additional four H-bonds with the RBD, involving the side chains of 154 VH R97 and Q101 ( Figure 3B ). We further determined the unliganded structure of COVA1-155 16 Fab to 2.53 Å resolution and found that the CDR H3 distal region was not resolved due 156 to lack of electron density indicating its inherent flexibility ( Figure S6 ). CDR H1 and CDR 157 L2 of COVA1-16 also interact with the RBD, but much less so compared to CDR H3. The 158 VH T28 main chain and VH Y32 side chain in CDR H1 H-bond with D427 ( Figure 3C , Table 159 S2), whereas VL N53 in CDR L2 H-bonds with RBD R408 ( Figure 3D , Table S2 ). Compared to the ACE2-binding site, the COVA1-16 epitope is much more highly Figure 4E and Figure S7 ). The COVA1-16 epitope is completely buried 177 at the center of the trimer in the interface between the S1 and S2 domains and is largely 178 hydrophilic ( Figure S9 ). The polar side chains of K378, Q414, R408, and D427, which are 179 involved in binding to COVA1-16, are all very close to the interface with adjacent 180 protomers in the S trimer. Interestingly, the R408 side chain, which is positioned by Q414 The Fabs were purified with a CaptureSelect™ CH1-XL Affinity Matrix (Thermo Fisher Dashed lines indicate hydrogen bonds. Interface residues are calculated using PISA [54] . The S1 segment from the third protomer is omitted to clarify the view of the interfaces that 736 the COVA1-16 epitope makes with the S2 domain. 31 Competition between COVA1-16 IgG, CR3022 IgG, and Fc-tagged ACE2 was measured A pneumonia 40 Sensorgrams for binding of COVA1-16 to SARS-CoV-2 42 RBD and SARS-CoV RBD. (A-B) Binding kinetics of COVA1-16 Fab and IgG SARS-CoV-2 RBD and (B) SARS-CoV RBD were measured by biolayer interferometry 44 (BLI) with RBD on the biosensor and antibody in solution Dissociation constants 46 (KD) for IgG and Fab were obtained using a 1:2 bivalent model and 1:1 binding model, 47 respectively, which are represented by the black lines. Representative results of two 48 replicates for each experiment are shown RBD loading concentration on the biosensor and the dissociation constant of Supplementary Figure 5. Sensorgrams for binding of COVA1-16 wild-type and VH 54 R100bS mutant Fabs to SARS-CoV-2 RBD. Binding kinetics of COVA1-16 wild-type and 55 VH R100bS mutant Fab to SARS-CoV-2 RBD were measured by biolayer interferometry 56 (BLI) with RBD on the biosensor and antibody in solution Representative results of two replicates for each experiment 59 are shown. Unlike Figure S4, which used HEK293F-expressed SARS-CoV-2, the 60 experiment here used insect cell-expressed SARS-CoV-2 Supplementary Figure 6. CDR H3 of COVA1-16 Fab is disordered in its unliganded 63 apo form. (A) In the crystal structure of the RBD-bound form of COVA1-16 Fab CDR H3 loop is completely ordered (red). (B) In the crystal structure of the apo form of 65 COVA1-16, the distal end of the CDR H3 loop is intrinsically disordered or flexible Amino-acid sequences of RBDs from SARS-CoV-2, SARS-CoV, and 69 other SARS-related coronavirus (SARSr-CoV) strains are aligned. COVA1-16 epitope 70 residues are highlighted in cyan Conserved residues are indicated by small black dots on the top of the alignment Neutralization 145 of SARS-CoV-2 by destruction of the prefusion spike Epub 2020/06/26 Cross-149 neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody Epub 2020/05/19 Structure, 153 function, and antigenicity of the SARS-CoV-2 spike glycoprotein Shape complementarity at protein/protein interfaces Cryo-160 EM structure of the 2019-nCoV spike in the prefusion conformation Site-specific glycan 164 analysis of the SARS-CoV-2 spike MolProbity: all-atom structure validation for macromolecular crystallography The epitope of COVA1-16 is outlined and shows its largely polar nature.